Methylation Diet and Lifestyle Study

NCT ID: NCT03472820

Last Updated: 2024-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The maintenance of health and the progression of disease are associated with an individual's genetic make-up and environmental factors, including lifestyle choices (such as diet, exercise, behaviors, stressors, sleep, tobacco and alcohol use), environmental exposures and socioeconomic determinants. Environmental factors have been shown to influence, sometimes rapidly, epigenetic processes thereby influencing genetic expression. Regulation of the human genome by the epigenome is now regarded as a cornerstone, heritable, physiologic process, playing a key role in phenotypic expression of health and disease.

DNA methylation is a well-researched, primary epigenetic process. Aberrant DNA methylation resulting in hyper- or hypomethylated regions of the genome, generally results in inhibition or expression of certain genes and has been associated with the pathogenesis of numerous conditions, ranging from inflammation and accelerated aging, to cancer, autoimmunity, diabetes, heart disease, dementia, allergic disease, posttraumatic stress disease and others. Likewise, certain healthy diet and lifestyle habits have been demonstrated to favorably influence DNA methylation patterns.

Understanding that environmental factors can potently and sometimes rapidly, favorably or negatively influence epigenetic expression, a short-term diet and lifestyle intervention may significantly augment DNA methylation expression.

The purpose of this study is to evaluate a 9-week diet and lifestyle intervention on patient-reported quality of life, symptoms, and DNA and biochemical methylation-related biomarkers in healthy males ages 50-72.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lifestyle Diet Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group

The intervention will be diet, lifestyle, exercise and stress management recommendations combined with taking two different supplements twice daily, in divided doses.

Group Type EXPERIMENTAL

Diet Recommendations

Intervention Type OTHER

Specific dietary guidelines will be outlined for participants.

Lifestyle Recommendations

Intervention Type OTHER

Participants are encouraged to average a minimum of 7 hours of sleep per night.

Exercise Recommendations

Intervention Type OTHER

Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.

Stress Management Recommendations

Intervention Type OTHER

Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.

PhytoGanix (tropical fruit flavor)

Intervention Type OTHER

Organic Superfruits \& Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.

UltraFlora Intensive Care

Intervention Type OTHER

Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.

Control Group

The control group will undergo the same testing measures as the intervention group, but will not have access to the education information or be instructed to change diet or lifestyle factors. They will have access to the information after the study is complete.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diet Recommendations

Specific dietary guidelines will be outlined for participants.

Intervention Type OTHER

Lifestyle Recommendations

Participants are encouraged to average a minimum of 7 hours of sleep per night.

Intervention Type OTHER

Exercise Recommendations

Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.

Intervention Type OTHER

Stress Management Recommendations

Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.

Intervention Type OTHER

PhytoGanix (tropical fruit flavor)

Organic Superfruits \& Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.

Intervention Type OTHER

UltraFlora Intensive Care

Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Males, ages 50-72

* Willing to adhere to 9 weeks of a dietary and lifestyle program including specific nutrition and exercise guidelines
* Willing to avoid any over-the-counter medications, supplements or herbal products for the length of the study, except short-term use (\<1 week) use at least 1 week before scheduled study visits
* Willing to have blood drawn three times and abstain from food or beverage intake for 10-12 hours before blood draws
* Willing to provide saliva samples
* Willing to track food intake, sleep, stress management techniques, and exercise daily
* Willing to drink a nutrient-enriched beverage and take a encapsulated probiotic daily
* Willing and able to use electronic devices and connect to the internet
* Able to speak, read and understand English

Exclusion Criteria

* • Currently taking any of the following prescription medications

* Proton pump inhibitors: omeprazole (Prilosec, Prilosec OTC); aspirin and omeprazole (Yosprala); lansoprazole (Prevacid, Prevacid IV, Prevacid 24-Hour); ;dexlansoprazole (Dexilent, Dexilent Solutab); rabeprazole (Aciphex, Aciphex Sprinkle); pantoprazole (Protonix)
* H2-blockers: nizatidine (Axid, Axid AR, Axid Pulvules); famotidine (Pepcid, Pepcid AC); cimetidine (Tagamet, Tagamet HB); ranitidine (Zantac)
* These classes of medications are excluded due to direct (due to nutrient requirements for metabolism) and indirect (through impaired digestion and assimilation of nutrients).

* Use of nutrition supplements or herbal products not prescribed by a licensed healthcare provider for a medical condition
* Currently following a prescribed dietary/lifestyle program or initiate within the 30 days prior to baseline
* Initiation of or changes to an exercise regimen within 30 days prior to baseline
* Use of nicotine, marijuana or cannabinoids (including CBD products) or recreational drugs/substances (such as but not limited to cocaine, phencyclidine \[PCP\], and methamphetamine) current/within the last 30 days or use during the study
* Have a diagnosis of cardiovascular disease, kidney disease, liver disease, diabetes, autoimmune disease, high blood pressure, or cancer (does not include basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix).
* Have a diagnosis of an immunodeficiency condition, such as Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS)
* Have a diagnosis of neurodegenerative conditions such as, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Multiple Sclerosis, or Alzheimer's disease.
* Excessive alcohol consumption (more than 4 drinks per day or 14 per week on average)
* Known sensitivity, intolerance or allergy to ingredients in the study supplements or in the recommended dietary therapy
* Currently receiving intravenous nutrient therapy
* Currently participating in another interventional research study or participated in another interventional study within the last 3 weeks prior to baseline
Minimum Eligible Age

50 Years

Maximum Eligible Age

72 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr. Kara Fitzgerald, ND

UNKNOWN

Sponsor Role collaborator

Metagenics, Inc.

INDUSTRY

Sponsor Role collaborator

National University of Natural Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NUNM Helfgott Research Institute

Portland, Oregon, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RB100217

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Researching Economical Adjuvants to Cancer Therapy
NCT07305259 RECRUITING EARLY_PHASE1